NYSEMKT: ASXCAsensus Surgical Inc Stock
$0.24-0.01 (-4%)
Updated Apr 24, 2024
ASXC Price
$0.24
Fair Value Price
N/A
Market Cap
$66.09M
52 Week Low
$0.20
52 Week High
$0.70
P/E
-0.78x
P/B
1.98x
P/S
9.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.58M
Earnings
-$78.43M
Gross Margin
-53.4%
Operating Margin
-910.8%
Profit Margin
-914.5%
Debt to Equity
0.77
Operating Cash Flow
-$64M
Beta
0.94
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ASXC Overview
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company's products include Senhance System, a multi-port robotic surgery system that allows multiple robotic arms to control instruments and a camera; and SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform. It offers its products directly and through distributors in Europe, the United States, Japan, Taiwan, and other select countries. The company was founded in 2006 and is based in Morrisville, North Carolina.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ASXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ASXC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ASXC is good value based on its book value relative to its share price (1.98x), compared to the US Medical Devices industry average (3.73x)
P/B vs Industry Valuation
ASXC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ASXC due diligence checks available for Premium users.
Be the first to know about important ASXC news, forecast changes, insider trades & much more!
ASXC News
Valuation
ASXC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.78x
Industry
30.46x
Market
41.27x
ASXC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.98x
Industry
3.73x
ASXC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ASXC's financial health
Profit margin
Revenue
$5.4M
Net Income
-$17.2M
Profit Margin
-317.3%
ASXC's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ASXC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$59.1M
Liabilities
$25.7M
Debt to equity
0.77
ASXC's short-term assets ($36.39M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ASXC's short-term assets ($36.39M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ASXC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ASXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.4M
Investing
$7.4M
Financing
$172.0k
ASXC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ASXC vs Medical Device Stocks
Asensus Surgical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.